AQUINOX PHARMACEUTICALS, INC Contracts & Agreements

Nonexclusive License Agreement between Neurogene Inc. and the Board of Trustees of the Leland Stanford Junior University dated August 6, 2024 (Filed With SEC on November 18, 2024)

Securities Purchase Agreement, dated November (Filed With SEC on November 4, 2024)

Form of Pre-Funded Warrant (Filed With SEC on November 4, 2024)

Form of Registration Rights Agreement (Filed With SEC on November 4, 2024)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on May 10, 2024)

Amended and Restated Consulting Agreement with Stuart Cobb Consulting Ltd. dated April 19, 2024 (Filed With SEC on May 10, 2024)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on May 10, 2024)

Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 18, 2024)

Form of Separation Agreement, by and between Neoleukin Therapeutics, Inc. and Sean Smith (Filed With SEC on December 19, 2023)

Fourth Amendment to the Consulting Agreement, dated January 1, 2023, by and between Neurogene Inc. and Stuart Cobb Consulting Ltd (Filed With SEC on December 19, 2023)

Third Amendment to the Consulting Agreement, dated April 1, 2022, by and between Neurogene Inc. and Stuart Cobb Consulting Ltd (Filed With SEC on December 19, 2023)

Second Amendment to the Consulting Agreement, dated January 1, 2020, by and between Neurogene Inc. and Stuart Cobb Consulting Ltd (Filed With SEC on December 19, 2023)

First Amendment to the Consulting Agreement, dated July 13, 2020, by and between Neurogene Inc. and Stuart Cobb Consulting Ltd (Filed With SEC on December 19, 2023)

Consulting Agreement, dated December 12, 2018, by and between Neurogene Inc. and Stuart Cobb Consulting Ltd (Filed With SEC on December 19, 2023)

Employment Letter, dated January 7, 2019, by and between Neurogene Inc. and Rachel McMinn (Filed With SEC on December 19, 2023)

Employment Letter, dated September 1, 2019, by and between Neurogene Inc. and Christine Mikail Cvijic (Filed With SEC on December 19, 2023)

Consulting Agreement, dated December 17, 2023, by and between Neoleukin Therapeutics, Inc. and Donna Cochener (Filed With SEC on December 19, 2023)

Form of Separation Agreement, by and between Neoleukin Therapeutics, Inc. and Donna Cochener (Filed With SEC on December 19, 2023)

Neurogene Inc. 2023 Employee Stock Purchase Plan (Filed With SEC on December 19, 2023)

Neurogene Inc. 2023 Equity Incentive Plan (Filed With SEC on December 19, 2023)

Form of Indemnification Agreement entered into between Neurogene Inc. and each of its directors and its executive officers (Filed With SEC on December 19, 2023)

Amendment 1 to the Master Research Collaboration Agreement, dated November 29, 2023, by and between Neurogene Inc. and The University Court of The University of Edinburgh (Filed With SEC on December 19, 2023)

Contingent Value Rights Agreement, dated December 18, 2023, by and among Neoleukin Therapeutics, Inc., Equiniti Trust Company, LLC and Donna Cochener (Filed With SEC on December 19, 2023)

Form of Revised CVR Agreement (Filed With SEC on December 4, 2023)

Separation Agreement dated March 31, 2023, by and between Neoleukin Therapeutics, Inc. and Priti Patel (Filed With SEC on May 8, 2023)

Separation Agreement dated March 6, 2023 and effective March 31, 2023, by and between Neoleukin Therapeutics, Inc. and Jonathan Drachman (Filed With SEC on May 8, 2023)

Employment Agreement Amendment dated as of April 3, 2023 and effective March 31, 2023, by and between Neoleukin Therapeutics, Inc. and Sean Smith (Filed With SEC on May 8, 2023)

Employment Agreement dated (Filed With SEC on May 8, 2023)

Employment Agreement Amendment dated as of April 3, 2023 and effective March 31, 2023, by and between Neoleukin Therapeutics, Inc. and Donna Cochener (Filed With SEC on May 8, 2023)

Employment Agreement, dated March 4, 2022, by and between Neoleukin Therapeutics, Inc. and Donna Cochener (Filed With SEC on March 20, 2023)

Amendment No. 2 to Exclusive Start-Up License Agreement, dated December 15, 2021, by and between the University of Washington and Neoleukin Therapeutics, Inc (Filed With SEC on March 1, 2022)

Employment Agreement, dated April 14, 2021, by and between Neoleukin Therapeutics, Inc. and Priti Patel (Filed With SEC on March 1, 2022)

ATM Equity Offering Sales Agreement, dated November 4, 2021, by and between Neoleukin Therapeutics, Inc. and BofA Securities, Inc (Filed With SEC on November 4, 2021)

Neoleukin Therapeutics, Inc. Amended and Restated 2014 Equity Incentive Plan (Filed With SEC on May 14, 2021)

Second Amendment to Lease, dated March 24, 2021, by and between Neoleukin Therapeutics, Inc. and ARE-Seattle No. 28, LLC (Filed With SEC on May 12, 2021)

First Amendment to Lease, dated November 5, 2020, by and between Neoleukin Therapeutics, Inc. and ARE-Seattle No. 28, LLC (Filed With SEC on March 25, 2021)

Amendment No. 1 to Exclusive Start-Up License Agreemen (Filed With SEC on March 25, 2021)

Executive Employment Agreement, dated September 29, 2020, by and between Neoleukin Therapeutics, Inc., and Holly Vance (Filed With SEC on March 25, 2021)

Purchase Order, dated November 25, 2020, by and between Neoleukin Therapeutics, Inc. and Rigaku Americas Corporation (Filed With SEC on March 25, 2021)

Forms of Restricted Stock Unit Agreement and Restricted Stock Unit Grant Notice for Registrants 2014 Equity Incentive Plan (Filed With SEC on August 12, 2020)

First Amendment, dated June 18, 2020, to Lease Agreement, dated September 23, 2019, by and between Neoleukin Therapeutics, Inc. and ARE-Eastlake Avenue No. 3, LLC (Filed With SEC on August 12, 2020)

Form of Pre-Funded Warrant (Filed With SEC on July 2, 2020)

Underwriting Agreement, dated July 1, 2020 (Filed With SEC on July 2, 2020)

Neoleukin Therapeutics, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on May 6, 2020)

Employment Agreement, dated March 16, 2020, by and between Neoleukin Therapeutics, Inc. and Robert Ho (Filed With SEC on May 6, 2020)

Amended and Restated Executive Employment Agreement, dated April 15, 2020, by and between Neoleukin Therapeutics, Inc., and Jonathan G. Drachman (Filed With SEC on April 17, 2020)

Lease Agreement, dated December 23, 2019, by and between Neoleukin Therapeutics, Inc. and ARE-Eastlake Avenue No. 3, LLC (Filed With SEC on March 12, 2020)

Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 12, 2020)

Exchange Agreement, dated December 17, 2019, by and among Neoleukin Therapeutics, Inc., 667, L.P. and Baker Brothers Life Sciences, L.P (Filed With SEC on December 19, 2019)

Form of Pre-Funded Warrant (Filed With SEC on December 19, 2019)

Underwriting Agreement, dated December 17, 2019 (Filed With SEC on December 19, 2019)

Neoleukin Therapeutics, Inc. 2014 Equity Incentive Plan, as amended November 12, 2019 (Filed With SEC on November 14, 2019)

Lease Agreement, dated September 23, 2019, by and between Neoleukin Therapeutics, Inc. and ARE-Eastlake Avenue No. 3, LLC (Filed With SEC on November 13, 2019)

Amendment No. 1 to the Facility Use Agreement, dated April 17, 2019, by and between Institute for Systems Biology and Neoleukin Therapeutics, Inc (Filed With SEC on August 12, 2019)

Facility Use Agreement, dated December 4, 2018, by and between Institute for Systems Biology and Neoleukin Therapeutics, Inc (Filed With SEC on August 12, 2019)

Exclusive Start-Up License Agreement, dated July 8, 2019, by and between the University of Washington and Neoleukin Therapeutics, Inc (Filed With SEC on August 12, 2019)

Transition Retention Agreement, dated August 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and Kamram Alam (Filed With SEC on August 6, 2019)

Employment Agreement, dated August 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and Jonathan G. Drachman (Filed With SEC on August 6, 2019)

Separation Agreement and Release, dated August 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and David J. Main (Filed With SEC on August 6, 2019)

Form of Lock-Up Agreement, by each of the parties named in each agreement therein (Filed With SEC on August 6, 2019)

Form of Support Agreement, by and among Aquinox Pharmaceuticals, Inc., Neoleukin Therapeutics, Inc. and each of the parties named in each agreement therein (Filed With SEC on August 6, 2019)

Agreement and Plan of Merger by and between Aquinox Pharmaceuticals, Inc., Apollo Sub, Inc., and Neoleukin Therapeutics, Inc., dated August 5, 2019 (Filed With SEC on August 6, 2019)

Executive Employment Agreement Amendment for David Main (Filed With SEC on August 1, 2019)

Executive Employment Agreement Amendment for Kamran Alam (Filed With SEC on August 1, 2019)

Early Termination Agreement by and between Aquinox Pharmaceuticals (Canada), Inc. and Astellas US LLC, effective as of November 8, 2018 (Filed With SEC on March 7, 2019)

Form of Executive Employment Agreement Amendment (AQXP Canada) (Filed With SEC on November 7, 2018)

Executive Employment Agreement Amendment for David Main (Filed With SEC on November 7, 2018)

Exclusive License and Collaboration Agreement by and between Aquinox Pharmaceuticals (Canada), Inc. and Astellas US LLC, effective as of May 9, 2018 (Filed With SEC on August 8, 2018)

First Amendment to Lease between Google Inc. and Aquinox Pharmaceuticals, Inc. dated January 9, 2017 (Filed With SEC on March 12, 2018)

Office Space Lease between CCF RPP Bayhill, LLC, and Aquinox Pharmaceuticals, Inc. dated December 10, 2015 (Filed With SEC on March 12, 2018)

5,350,000 Shares Aquinox Pharmaceuticals, Inc. COMMON STOCK, PAR VALUE $0.000001 PER SHARE UNDERWRITING AGREEMENT September 19, 2016 (Filed With SEC on September 20, 2016)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on September 20, 2016)

Agreement (Filed With SEC on March 14, 2016)

EXECUTIVE EMPLOYMENT AGREEMENT for [Name] (Filed With SEC on March 14, 2016)

OFFICE SPACE LEASE 560677 B.C. LTD. Landlord and AQUINOXPHARMACEUTICALS (CANADA) INC. Tenant Suite 450 887 GreatNorthern Way, Vancouver, BC Rentable Area: approximately 10,946... (Filed With SEC on February 10, 2016)

5,500,000 Shares Aquinox Pharmaceuticals, Inc. COMMON STOCK, PAR VALUE $0.000001 PER SHARE UNDERWRITING AGREEMENT September 9, 2015 (Filed With SEC on September 10, 2015)

AQUINOX PHARMACEUTICALS, INC. $25,000,000 SALESAGREEMENT (Filed With SEC on April 1, 2015)

Form of Executive Employment Agreement (Filed With SEC on November 4, 2014)

[] Shares AQUINOX PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT (Filed With SEC on February 28, 2014)

ASSET PURCHASE AGREEMENT among AQUINOXPHARMACEUTICALS INC. and BIOLIPOX AB (publ.) and OREXO AB (publ.) Dated: August 19th, 2009 (Filed With SEC on February 28, 2014)

CONSENT TO SUBLEASE (Filed With SEC on February 28, 2014)

AMENDED & RESTATED SHAREHOLDERS AGREEMENT (Filed With SEC on January 28, 2014)

SCHEDULE A AQUINOX PHARMACEUTICALS INC. AQUINOX PHARMACEUTICALS (USA) INC. OPTION AGREEMENT (Filed With SEC on January 28, 2014)

ASSET PURCHASE AGREEMENT among AQUINOXPHARMACEUTICALS INC. and BIOLIPOX AB (publ.) and OREXO AB (publ.) Dated: August 19th, 2009 (Filed With SEC on January 28, 2014)

LOAN AGREEMENT (Filed With SEC on January 28, 2014)

SECURITY AGREEMENT (Filed With SEC on January 28, 2014)

David Main (Filed With SEC on January 28, 2014)

INDEMNIFICATION AGREEMENT (Filed With SEC on January 28, 2014)

AQUINOX PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN OPTION AGREEMENT (INCENTIVE STOCK OPTION OR NONSTATUTORY STOCKOPTION) (U.S. OPTIONHOLDERS) (Filed With SEC on January 28, 2014)

AQUINOX PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:JANUARY 12, 2014 APPROVED BY THE STOCKHOLDERS:JANUARY 27, 2014 EFFECTIVE DATE:[ ], 2014... (Filed With SEC on January 28, 2014)

AMENDED AND RESTATED QUALIFICATION AND REGISTRATION RIGHTS AGREEMENT (Filed With SEC on January 28, 2014)

AQUINOX PHARMACEUTICALS INC. AQUINOX PHARMACEUTICALS (USA) INC. JOINT CANADIAN STOCK OPTION PLAN AS AMENDED AND RESTATED AS OF JUNE 8, 2007 (Filed With SEC on January 28, 2014)

WARRANT TO PURCHASE STOCK (Filed With SEC on January 28, 2014)

AMENDED & RESTATED EXCHANGE AGREEMENT (Filed With SEC on January 28, 2014)

AMENDMENT NO. 3 TO SHAREHOLDERS AGREEMENT (Filed With SEC on January 28, 2014)

AMENDMENT NO. 2 TO SHAREHOLDERS AGREEMENT (Filed With SEC on January 28, 2014)

AMENDMENT TO SHAREHOLDERS AGREEMENT (Filed With SEC on January 28, 2014)

OFFER TO LEASE (Filed With SEC on January 28, 2014)

Category

Industry

Companies

Contracts

AQUINOX PHARMACEUTICALS, INC Contracts & Agreements